NCT03569371View on ClinicalTrials.gov

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

April 22, 2019

Study Completion Date

April 22, 2019

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

INCB054707

INCB054707 administered once daily orally with water without regard to food for 8 weeks.

Trial Locations (4)

10065

Investigative Site, New York

17033

Investigative Site, Hershey

33624

Investigative Site, Tampa

90045

Investigative Site, Los Angeles

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT03569371 - A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter